1) Virological diagnosis by RT-PCR of infection to SARS-CoV-2.2) Contact or suspect of COVID-19 at the time of inclusion.3) Subjects at high risk of exposure to SARS-CoV-2 infection (contacts of confirmed cases, health workers in the 1st line of medical care [Emergency, ICU, other risk areas]).4) Acute infection in the last 15 days or presence, at the time of inclusion in the study, of signs and symptoms such as: fever, cough, dyspnea or anosmia / ageusia.5) Chronic, autoimmune or endocrine-metabolic diseases decompensated at the time of inclusion.6) Body mass index =18 or = 35 Kg / m2.7) Subjects with tattoos in both deltoid regions.8) Administration of any research product in the last three months.9) Subject treated in the last three months or with any medical condition that requires an immunomodulator (interferon, transfer factor, biomodulin T, thymosin, etc.), steroid or cytostatic, during the study.10) Have received blood, immunoglobulins or blood products in the three months prior to the start of the study.11) Known hypersensitivity to thiomersal and any of the components of the formulation under study.12) History or suspicion of alcoholism or drug dependence.13) Pregnancy or breastfeeding. Woman of reproductive age not using contraceptives or planning pregnancy.14) Obvious mental incapacity to issue consent and act accordingly with the study.

1) Virological diagnosis by RT-PCR of infection to SARS-CoV-2.2) Contact or suspect of COVID-19 at the time of inclusion.3) Subjects at high risk of exposure to SARS-CoV-2 infection (contacts of confirmed cases, health workers in the 1st line of medical care [Emergency, ICU, other risk areas]).4) Acute infection in the last 15 days or presence, at the time of inclusion in the study, of signs and symptoms such as: fever, cough, dyspnea or anosmia / ageusia.5) Chronic, autoimmune or endocrine-metabolic diseases decompensated at the time of inclusion.6) Body mass index =18 or = 35 Kg / m2.7) Subjects with tattoos in both deltoid regions.8) Administration of any research product in the last three months.9) Subject treated in the last three months or with any medical condition that requires an immunomodulator (interferon, transfer factor, biomodulin T, thymosin, etc.), steroid or cytostatic, during the study.10) Have received blood, immunoglobulins or blood products in the three months prior to the start of the study.11) Known hypersensitivity to thiomersal and any of the components of the formulation under study.12) History or suspicion of alcoholism or drug dependence.13) Pregnancy or breastfeeding. Woman of reproductive age not using contraceptives or planning pregnancy.14) Obvious mental incapacity to issue consent and act accordingly with the study.

1) Virological diagnosis by RT-PCR of infection to SARS-CoV-2. 2) Contact or suspect of COVID-19 at the time of inclusion. 3) Subjects at high risk of exposure to SARS-CoV-2 infection (contacts of confirmed cases, health workers in the 1st line of medical care [Emergency, ICU, other risk areas]). 4) Acute infection in the last 15 days or presence, at the time of inclusion in the study, of signs and symptoms such as: fever, cough, dyspnea or anosmia / ageusia. 5) Chronic, autoimmune or endocrine-metabolic diseases decompensated at the time of inclusion. 6) Body mass index <=18 or >= 35 Kg / m2. 7) Subjects with tattoos in both deltoid regions. 8) Administration of any research product in the last three months. 9) Subject treated in the last three months or with any medical condition that requires an immunomodulator (interferon, transfer factor, biomodulin T, thymosin, etc.), steroid or cytostatic, during the study. 10) Have received blood, immunoglobulins or blood products in the three months prior to the start of the study. 11) Known hypersensitivity to thiomersal and any of the components of the formulation under study. 12) History or suspicion of alcoholism or drug dependence. 13) Pregnancy or breastfeeding. Woman of reproductive age not using contraceptives or planning pregnancy. 14) Obvious mental incapacity to issue consent and act accordingly with the study.

1) Virological diagnosis by RT-PCR of infection to SARS-CoV-2. 2) Contact or suspect of COVID-19 at the time of inclusion. 3) Subjects at high risk of exposure to SARS-CoV-2 infection (contacts of confirmed cases, health workers in the 1st line of medical care [Emergency, ICU, other risk areas]). 4) Acute infection in the last 15 days or presence, at the time of inclusion in the study, of signs and symptoms such as: fever, cough, dyspnea or anosmia / ageusia. 5) Chronic, autoimmune or endocrine-metabolic diseases decompensated at the time of inclusion. 6) Body mass index <=18 or >= 35 Kg / m2. 7) Subjects with tattoos in both deltoid regions. 8) Administration of any research product in the last three months. 9) Subject treated in the last three months or with any medical condition that requires an immunomodulator (interferon, transfer factor, biomodulin T, thymosin, etc.), steroid or cytostatic, during the study. 10) Have received blood, immunoglobulins or blood products in the three months prior to the start of the study. 11) Known hypersensitivity to thiomersal and any of the components of the formulation under study. 12) History or suspicion of alcoholism or drug dependence. 13) Pregnancy or breastfeeding. Woman of reproductive age not using contraceptives or planning pregnancy. 14) Obvious mental incapacity to issue consent and act accordingly with the study.